Details for Patent: 8,846,695
✉ Email this page to a colleague
Which drugs does patent 8,846,695 protect, and when does it expire?
Patent 8,846,695 protects JENTADUETO and TRADJENTA and is included in two NDAs.
Protection for JENTADUETO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifteen patent family members in fourteen countries.
Summary for Patent: 8,846,695
| Title: | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
| Abstract: | The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for improving glycemic control in type 2 diabetes patients with inadequate glycemic control despite metformin therapy. |
| Inventor(s): | Dugi; Klaus (Dresden, DE) |
| Assignee: | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) |
| Application Number: | 13/143,370 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,846,695 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,846,695
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | JENTADUETO | linagliptin; metformin hydrochloride | TABLET;ORAL | 201281-003 | Jan 30, 2012 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Boehringer Ingelheim | JENTADUETO | linagliptin; metformin hydrochloride | TABLET;ORAL | 201281-001 | Jan 30, 2012 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Boehringer Ingelheim | JENTADUETO | linagliptin; metformin hydrochloride | TABLET;ORAL | 201281-002 | Jan 30, 2012 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Boehringer Ingelheim | TRADJENTA | linagliptin | TABLET;ORAL | 201280-001 | May 2, 2011 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,846,695
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 09150159 | Jan 7, 2009 | |
| PCT Information | |||
| PCT Filed | January 07, 2010 | PCT Application Number: | PCT/EP2010/050103 |
| PCT Publication Date: | July 15, 2010 | PCT Publication Number: | WO2010/079197 |
International Family Members for US Patent 8,846,695
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 074990 | ⤷ Try a Trial | |||
| Australia | 2010204331 | ⤷ Try a Trial | |||
| Brazil | PI1006144 | ⤷ Try a Trial | |||
| Canada | 2745039 | ⤷ Try a Trial | |||
| Chile | 2011001635 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
